CJC-1295 + Ipamorelin Stack: The Ultimate Guide

Understanding the CJC-1295/Ipamorelin Stack

The combination of CJC-1295 (without DAC, also known as Modified GRF 1-29) and Ipamorelin is one of the most popular growth hormone (GH) peptide stacks in research and clinical use. This combination works by targeting two different receptors in the pituitary gland to produce a synergistic increase in growth hormone release while maintaining the body's natural pulsatile secretion pattern.

How Each Peptide Works

CJC-1295 (Mod GRF 1-29)

CJC-1295 without DAC is a 29-amino acid analog of growth hormone releasing hormone (GHRH). It binds to the GHRH receptor on pituitary somatotroph cells, amplifying the GH pulse when the body is naturally primed to release growth hormone. Key characteristics include a half-life of approximately 30 minutes and the ability to increase both the amplitude and duration of natural GH pulses without disrupting the pulsatile pattern.

Ipamorelin

Ipamorelin is a selective growth hormone secretagogue (GHS) that acts on the ghrelin/GHS receptor (GHS-R1a). Unlike older GHS peptides such as GHRP-6 and GHRP-2, Ipamorelin is highly selective for GH release and does not significantly affect cortisol, prolactin, or appetite. This selectivity makes it one of the cleanest GH secretagogues available.

The Synergy: Why the Stack Works

The combination produces effects greater than either peptide alone because of their complementary mechanisms:

• Dual receptor activation -- CJC-1295 activates the GHRH receptor while Ipamorelin activates the GHS receptor. These two pathways converge on the somatotroph cell to produce additive GH release.
• Preserved pulsatility -- Both peptides work with the body's natural feedback mechanisms. The negative feedback loop via somatostatin remains intact, preventing excessive or unnatural GH levels.
• Amplified pulse magnitude -- Research shows the combination can increase GH pulse amplitude by 3-5x compared to baseline, while maintaining normal pulse frequency.
• Minimal side effects -- Because neither peptide disrupts the hypothalamic-pituitary axis or significantly affects other hormones, the side effect profile remains favorable.

Benefits Observed in Research

Growth hormone elevation from this stack has been associated with several beneficial effects in research:

• Increased lean body mass and reduced body fat percentage
• Improved sleep quality, particularly deep (slow-wave) sleep
• Enhanced recovery from exercise and injury
• Improved skin elasticity and collagen synthesis
• Better bone mineral density over long-term use
• Potential cognitive benefits through GH/IGF-1 signaling

Dosing Protocol and Peptide Calculator Settings

Standard Protocol

• CJC-1295 (no DAC): 100 mcg per injection
• Ipamorelin: 100-200 mcg per injection
• Frequency: 1-3 times daily
• Timing: On an empty stomach (at least 2 hours post-meal, 30 min before next meal)
• Preferred injection times: Upon waking, post-workout, and/or before bed

Peptide Calculator Example

Using the Peptide Calculator Plus with typical vial sizes:

• CJC-1295 (2 mg vial) reconstituted with 2 mL BAC water = 1,000 mcg/mL. For 100 mcg, draw 10 units.
• Ipamorelin (5 mg vial) reconstituted with 2 mL BAC water = 2,500 mcg/mL. For 200 mcg, draw 8 units.

Both peptides can be drawn into the same syringe for a single injection. Draw CJC-1295 first, then Ipamorelin.

Timing and Meal Considerations

Growth hormone release is significantly blunted by elevated blood glucose and insulin. For maximum effectiveness, injections should be administered when blood sugar is low. The three optimal windows are fasting in the morning before breakfast, at least 2 hours after the last meal in the afternoon, and 30-60 minutes before bedtime (at least 2-3 hours after dinner).

CJC-1295 with DAC vs Without DAC

It is important to distinguish between the two versions of CJC-1295. The DAC (Drug Affinity Complex) version binds to albumin in the blood, extending its half-life to 6-8 days. This creates a constant, non-pulsatile elevation of GH -- which is not physiological and may lead to desensitization of GH receptors over time. CJC-1295 without DAC (Mod GRF 1-29) is preferred for the Ipamorelin stack because it preserves the natural pulsatile release pattern.

Side Effects

The CJC-1295/Ipamorelin stack is generally well-tolerated. Reported side effects include:

• Mild flushing or warmth after injection (common, resolves in minutes)
• Increased hunger (more common with Ipamorelin, though less than GHRP-6)
• Occasional headache
• Tingling or numbness in extremities (a sign of GH elevation)
• Water retention (mild, usually stabilizes within 1-2 weeks)

Cycle Length and Breaks

Most protocols recommend running the CJC-1295/Ipamorelin stack for 8-12 weeks followed by a 4-week break. This cycling approach helps prevent receptor desensitization and maintains the body's responsiveness to the peptides. Some clinicians prescribe continuous use at lower frequencies (once daily before bed) for anti-aging applications.